Noven Pharmaceutical has announced its decision to appoint Dr. Naruhito Higo as Chief Executive Officer effective October 1, 2019, succeeding Jeff Mihm who has tendered his resignation. Noven is a stand-alone operating subsidiary of Japan-based Hisamitsu Pharmaceutical Co., Inc., serving as Hisamitsu’s U.S. platform in prescription pharmaceuticals, and helping Hisamitsu bring the benefits of patch therapy to patients around the world.

Dr. Naruhito Higo, Chairman of Noven’s Board of Directors, has been with Hisamitsu since 1985, and a member of Hisamitsu’s Board of Directors since 2012. From 2007 to 2017, he served as the Head of Research and Development at Hisamitsu. Following his appointment as Chairman of Noven’s Board of Directors in 2017, Dr. Higo relocated to Miami, Florida. Dr. Higo said: “On behalf of my Hisamitsu and Noven colleagues I offer sincere thanks and appreciation to Jeff for his contributions during his tenure at Noven, and wish him continued success in future endeavors.”

The Hisamitsu Board of Directors believes that Dr. Higo’s rich history with Hisamitsu, his role as Chairman of the Board for Noven, and his vision for future Noven/Hisamitsu strategy, position him as an ideal choice to lead the organization in advancing our mission of benefiting patients around the world with transdermal drug delivery systems (TDDS).

“I am privileged to lead Noven as we leverage our collaboration with our parent company and remain committed to our TDDS mission. I appreciate the trust that the Noven Board of Directors and Hisamitsu have placed in the Noven team,” said Dr. Higo.